Based on findings from previous studies and our observations on the improved prognosis of OC in the high‐expressing CCL18 group and the low‐expressing CCL18 group, it is reasonable to assume that the expression of CCL18 in the tumor environment may attract and activate immune cells, thereby enhancing the immune response against malignant tumors. The gene discussed is CCL18; the disease is neoplasm.